Doximity, Inc. — Form 10-Q Summary
Reporting period: Second quarter of fiscal 2024, the three months ended September 30, 2023; year-to-date figures cover the six months ended that date. Comparisons are with the corresponding 2022 periods. The filing was signed November 9, 2023.
Business context
Doximity operates a digital platform for healthcare professionals and sells subscription-based Marketing and Hiring Solutions, primarily to pharmaceutical companies and health systems. Management reports one operating segment. Subscription revenue accounted for about 94% of revenue in both the quarter and six-month period.
Financial performance
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue | $113.6 million, up 11% from $102.2 million | $222.1 million, up 15% from $192.8 million |
| Gross profit / margin | $100.9 million / 89%, versus $89.0 million / 87% | $196.2 million / 88%, versus $166.5 million / 86% |
| Operating income | $33.8 million, versus $32.1 million | $63.5 million, versus $53.8 million |
| Net income / diluted EPS | $30.6 million / $0.15, versus $26.3 million / $0.12 | $59.0 million / $0.28, versus $48.7 million / $0.23 |
| Adjusted EBITDA / margin | $54.2 million / 48%, versus $46.0 million / 45% | $100.7 million / 45%, versus $79.5 million / 41% |
| Operating cash flow / free cash flow | Not provided as a quarterly comparison in this filing | $70.1 million / $67.3 million, versus $84.3 million / $80.3 million |
Adjusted EBITDA and free cash flow are non-GAAP measures. Subscription revenue rose $11.3 million in the quarter and $28.9 million year to date. Management attributed growth to new customers and expansion among existing customers; average revenue per existing Marketing Solutions customer increased 17% for the quarter and 20% for the six-month period.
Balance sheet, liquidity and capital allocation
- At September 30, 2023, cash and cash equivalents were $108.4 million and marketable securities were $621.5 million. Management cited $729.9 million of these combined resources and expects them to meet working-capital and capital needs for at least 12 months.
- Total assets were $1.026 billion and total liabilities $154.1 million. The filing reports no borrowings or debt balance; operating lease liabilities totaled $15.1 million.
- Six-month operating cash flow fell to $70.1 million from $84.3 million. Management cited cash tax payments, lower deferred revenue and other working-capital movements. Investing activities provided $67.2 million, largely from securities maturities and sales; financing activities used $186.9 million, primarily for share repurchases.
- The company repurchased 7.54 million shares during the quarter and reported $186.2 million of cash repurchases for the six months. Cumulative repurchases under the applicable programs were 8.72 million shares for $207.5 million, including commissions and excise taxes. At September 30, $63.7 million remained authorized under those programs.
Material changes, outlook and risks
- Restructuring: In August, Doximity announced a plan to reduce its workforce by about 10%; actions were substantially completed by September 30. The quarter included $7.9 million in charges: $4.3 million for severance and benefits and $3.6 million for accelerated equity vesting. Management said the plan was intended to simplify operations and align resources with priorities.
- Profitability drivers: Higher interest income contributed to other income, which rose to $5.9 million for the quarter and $10.7 million year to date, from $0.9 million and $1.7 million, respectively. Management expects gross margin to remain relatively steady near term, with quarterly fluctuations possible, and expects certain operating expenses to increase in absolute dollars.
- Guidance: The filing does not provide specific revenue or earnings guidance. Management says existing liquidity should be sufficient for at least the next 12 months, but future capital needs depend on growth, spending and repurchases; additional financing may be required in the future.
- Cash tax exposure: Required capitalization and amortization of research and development costs under the Tax Cuts and Jobs Act could reduce fiscal 2024 operating cash flow by approximately $15.7 million if not changed.
- Investment and operating risks: A hypothetical 100-basis-point interest-rate increase would have reduced the September 30 fair value of cash equivalents and marketable securities by an estimated $3.4 million. The company reported $12.0 million of unrealized investment losses, with no credit impairment recognized. It also noted exposure to competition, macroeconomic uncertainty, privacy and security, regulation, and other risks referenced in prior filings. No material legal loss contingency was recorded, and management reported effective disclosure controls.
- Subsequent event: On October 26, the board authorized a further $70 million share-repurchase program over 12 months; the filing says prior programs were completed by October 2023.
Important facts for investors to verify
- Whether subscription growth and customer expansion persist as net revenue retention declined to 114% from 128% a year earlier; the $100,000-plus TTM subscription customer count rose to 290 from 281.
- How the workforce reduction affects future costs, product development and growth, and how much of reported profitability reflects the $7.9 million restructuring charge and stock-based compensation.
- Whether operating cash flow recovers after falling year over year, including the effects of deferred revenue, tax payments and the R&D tax rule.
- The pace and funding of repurchases under the new authorization, and the impact on cash, share count and financial flexibility.
- Interest-rate sensitivity and the timing or potential realization of unrealized securities losses; the filing says Doximity does not intend to sell the affected securities and expects to hold them until maturity or cost recovery.